Research Article
The Value of PD-L1 Expression in Predicting the Efficacy of Anti-PD-1 or Anti-PD-L1 Therapy in Patients with Cancer: A Systematic Review and Meta-Analysis
Figure 4
Subgroup analyses for overall survival comparing anti-PD-1/PD-L1 drugs to control treatments in NSCLC patients with PD-L1 expression statuses ≥1% (a) and <1% (b). NSCLC: nonsmall cell lung cancer; PD-1: programmed death 1; PD-L1: programmed death-ligand 1.
(a) |
(b) |